Dizal grants AstraZeneca worldwide rights to develop and commercialise Zegfrovy Dizal will receive an upfront payment of $600M, and milestone payments of up to $900M. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. SHANGHAI, July 14, 2026 /PRNewswire/ --...
Hence then, the article about dizal announces global exclusive license agreement with astrazeneca for zegfrovy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy )
Also on site :
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
- Labor Day, Patriot Day, Rosh Hashanah and More—Check Out All These September Holidays and Observances in 2026
- Bus crashes into parked cars at Portslade Station